

# Shuang-Jian Qiu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8165676/publications.pdf>

Version: 2024-02-01

78  
papers

3,465  
citations

201674

27  
h-index

168389

53  
g-index

80  
all docs

80  
docs citations

80  
times ranked

5240  
citing authors

#	ARTICLE	IF	CITATIONS
1	BRG1 regulates lipid metabolism in hepatocellular carcinoma through the PIK3AP1/PI3K/AKT pathway by mediating GLMP expression. <i>Digestive and Liver Disease</i> , 2022, 54, 692-700.	0.9	8
2	Antiviral therapy improves postoperative survival of patients with HBV-related hepatocellular carcinoma. <i>American Journal of Surgery</i> , 2022, , .	1.8	3
3	Dissecting Intra-Tumoral Changes Following Immune Checkpoint Blockades in Intrahepatic Cholangiocarcinoma via Single-Cell Analysis. <i>Frontiers in Immunology</i> , 2022, 13, 871769.	4.8	8
4	Adjuvant lenvatinib after radical resection in patients with hepatocellular carcinoma (HCC): Preliminary analysis of a prospective, multi-center, single-arm study.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16158-e16158.	1.6	2
5	MNS1 promotes hepatocarcinogenesis and metastasis via activating PI3K/AKT by translocating $\beta$ -catenin and predicts poor prognosis. <i>Liver International</i> , 2021, 41, 1409-1420.	3.9	4
6	Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF $\kappa$ B signaling pathways synergistically. <i>Clinical and Translational Medicine</i> , 2021, 11, e335.	4.0	27
7	Cancer-associated fibroblast-derived CXCL11 modulates hepatocellular carcinoma cell migration and tumor metastasis through the circUBAP2/miR-4756/IFIT1/3 axis. <i>Cell Death and Disease</i> , 2021, 12, 260.	6.3	56
8	Hepatic stellate cells promote intrahepatic cholangiocarcinoma progression via NR4A2/osteopontin/Wnt signaling axis. <i>Oncogene</i> , 2021, 40, 2910-2922.	5.9	13
9	Lenvatinib plus toripalimab as first-line treatment for advanced intrahepatic cholangiocarcinoma: A single-arm, phase 2 trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4099-4099.	1.6	6
10	Gemox chemotherapy in combination with anti-PD1 antibody toripalimab and lenvatinib as first-line treatment for advanced intrahepatic cholangiocarcinoma: A phase 2 clinical trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4094-4094.	1.6	14
11	Phase II study of lenvatinib in combination with GEMOX chemotherapy for advanced intrahepatic cholangiocarcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16163-e16163.	1.6	5
12	Dissecting spatial heterogeneity and the immune-evasion mechanism of CTCs by single-cell RNA-seq in hepatocellular carcinoma. <i>Nature Communications</i> , 2021, 12, 4091.	12.8	90
13	TM2D1 contributes the epithelial-mesenchymal transition of hepatocellular carcinoma via modulating AKT/ $\beta$ -catenin axis. <i>American Journal of Cancer Research</i> , 2021, 11, 1557-1571.	1.4	1
14	Establishment of a hepatocellular carcinoma patient-derived xenograft platform and its application in biomarker identification. <i>International Journal of Cancer</i> , 2020, 146, 1606-1617.	5.1	32
15	TGM3 promotes epithelial-mesenchymal transition and hepatocellular carcinogenesis and predicts poor prognosis for patients after curative resection. <i>Digestive and Liver Disease</i> , 2020, 52, 668-676.	0.9	15
16	Adjuvant apatinib treatment after resection of hepatocellular carcinoma with portal vein tumor thrombosis: a phase II trial. <i>Annals of Translational Medicine</i> , 2020, 8, 1301-1301.	1.7	11
17	Age-adjusted Charlson Comorbidity Index predicts survival in intrahepatic cholangiocarcinoma patients after curative resection. <i>Annals of Translational Medicine</i> , 2020, 8, 487-487.	1.7	25
18	Postoperative circulating tumor cells: An early predictor of extrahepatic metastases in patients with hepatocellular carcinoma undergoing curative surgical resection. <i>Cancer Cytopathology</i> , 2020, 128, 733-745.	2.4	19

#	ARTICLE	IF	CITATIONS
19	Hepatic stellate cells promote the progression of hepatocellular carcinoma through microRNA-1246-ROR1±-Wnt/β2-Catenin axis. <i>Cancer Letters</i> , 2020, 476, 140-151.	7.2	34
20	ROR1±-1 inhibits the proliferation, invasion, and migration of hepatocellular carcinoma MHCC97H via downregulation of chemokine CXCL5. <i>Cytokine</i> , 2020, 129, 155004.	3.2	14
21	&lt;p&gt;Role of Lipids and Apolipoproteins in Predicting the Prognosis of Hepatocellular Carcinoma After Resection&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 12867-12880.	2.0	7
22	Effect of postoperative apatinib treatment after resection of hepatocellular carcinoma with portal vein invasion: A phase II study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 514-514.	1.6	3
23	Clinical significance of herpes virus entry mediator expression in hepatitis B virusâ€related hepatocellular carcinoma. <i>Oncology Letters</i> , 2020, 20, 19.	1.8	8
24	KPNA3 Confers Sorafenib Resistance to Advanced Hepatocellular Carcinoma via TWIST Regulated Epithelial-Mesenchymal Transition. <i>Journal of Cancer</i> , 2019, 10, 3914-3925.	2.5	27
25	Chemotherapeutic perfusion of portal vein after tumor thrombectomy and hepatectomy benefits patients with advanced hepatocellular carcinoma: A propensity scoreâ€matched survival analysis. <i>Cancer Medicine</i> , 2019, 8, 6933-6944.	2.8	14
26	Prognostic Value and Predication Model of Microvascular Invasion in Patients with Intrahepatic Cholangiocarcinoma. <i>Journal of Cancer</i> , 2019, 10, 5575-5584.	2.5	28
27	Combined preoperative albumin-bilirubin (ALBI) and serum γ-glutamyl transpeptidase (GGT) predicts the outcome of hepatocellular carcinoma patients following hepatic resection. <i>Journal of Cancer</i> , 2019, 10, 4836-4845.	2.5	19
28	&lt;p&gt;Development and validation of a prognostic score predicting recurrence in resected combined hepatocellular cholangiocarcinoma&lt;/p&gt;. <i>Cancer Management and Research</i> , 2019, Volume 11, 5187-5195.	1.9	12
29	Tissue-infiltrating lymphocytes signature predicts survival in patients with early/intermediate stage hepatocellular carcinoma. <i>BMC Medicine</i> , 2019, 17, 106.	5.5	31
30	Inflammationâ€nutrition score predicts prognosis of patients with resectable hepatocellular carcinoma. <i>International Journal of Clinical Oncology</i> , 2019, 24, 825-835.	2.2	8
31	HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1. , 2019, 7, 77.		81
32	High expression of Oct4 and Nanog predict poor prognosis in intrahepatic cholangiocarcinoma patients after curative resection. <i>Journal of Cancer</i> , 2019, 10, 1313-1324.	2.5	9
33	CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110β and predicts poor prognosis. <i>Journal of Hematology and Oncology</i> , 2019, 12, 37.	17.0	150
34	Differential network analysis depicts regulatory mechanisms for hepatocellular carcinoma from diverse backgrounds. <i>Future Oncology</i> , 2019, 15, 3917-3934.	2.4	2
35	Clinical Characteristics and Prognostic Factors of Patients with Intrahepatic Cholangiocarcinoma with Fever: A Propensity Score Matching Analysis. <i>Oncologist</i> , 2019, 24, 997-1007.	3.7	9
36	S100A11 promotes cell proliferation via P38/MAPK signaling pathway in intrahepatic cholangiocarcinoma. <i>Molecular Carcinogenesis</i> , 2019, 58, 19-30.	2.7	15

#	ARTICLE	IF	CITATIONS
37	Daily decrease of post-operative alpha-fetoprotein by 9% discriminates prognosis of HCC: A multicenter retrospective study. <i>Aging</i> , 2019, 11, 11111-11123.	3.1	6
38	New nomogram predicts the recurrence of hepatocellular carcinoma in patients with negative preoperative serum AFP subjected to curative resection. <i>Journal of Surgical Oncology</i> , 2018, 117, 1540-1547.	1.7	40
39	Circulating Tumor Cells with Stem-Like Phenotypes for Diagnosis, Prognosis, and Therapeutic Response Evaluation in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 2203-2213.	7.0	102
40	Circulating Tumor Cells from Different Vascular Sites Exhibit Spatial Heterogeneity in Epithelial and Mesenchymal Composition and Distinct Clinical Significance in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 547-559.	7.0	112
41	A novel and validated prognostic nomogram based on liver fibrosis and tumor burden for patients with hepatocellular carcinoma after curative resection. <i>Journal of Surgical Oncology</i> , 2018, 117, 625-633.	1.7	16
42	Prognostic impact of lactic dehydrogenase to albumin ratio in hepatocellular carcinoma patients with Child&ndash;Pugh I who underwent curative resection: a prognostic nomogram study. <i>Cancer Management and Research</i> , 2018, Volume 10, 5383-5394.	1.9	14
43	BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1/2 and JNK/c-Jun pathways. <i>Cell Death and Disease</i> , 2018, 9, 1036.	6.3	31
44	Prognostic Nomogram Based on Histological Characteristics of Fibrotic Tumor Stroma in Patients Who Underwent Curative Resection for Intrahepatic Cholangiocarcinoma. <i>Oncologist</i> , 2018, 23, 1482-1493.	3.7	26
45	A Novel Risk prediction Model for Patients with Combined Hepatocellular-Cholangiocarcinoma. <i>Journal of Cancer</i> , 2018, 9, 1025-1032.	2.5	14
46	PDXliver: a database of liver cancer patient derived xenograft mouse models. <i>BMC Cancer</i> , 2018, 18, 550.	2.6	20
47	Surgical Treatment of Combined Hepatocellular-Cholangiocarcinoma is as Effective in Elderly Patients as it is in Younger Patients: A Propensity Score Matching Analysis. <i>Journal of Cancer</i> , 2018, 9, 1106-1112.	2.5	16
48	Prognostic Nomograms Stratify Survival of Patients with Hepatocellular Carcinoma Without Portal Vein Tumor Thrombosis After Curative Resection. <i>Oncologist</i> , 2017, 22, 561-569.	3.7	35
49	Preventive Inhibition of Liver Tumorigenesis by Systemic Activation of Innate Immune Functions. <i>Cell Reports</i> , 2017, 21, 1870-1882.	6.4	22
50	Circulating CD14 <sup>+</sup> HLA <sup>DR</sup> <sup>low</sup> myeloid-derived suppressor cells predicted early recurrence of hepatocellular carcinoma after surgery. <i>Hepatology Research</i> , 2017, 47, 1061-1071.	3.4	56
51	Preoperative Albumin-Bilirubin Score for Postoperative Solitary Hepatocellular Carcinoma within the Milan Criteria and Child-Pugh A Cirrhosis. <i>Journal of Cancer</i> , 2017, 8, 3862-3867.	2.5	23
52	Perioperative blood transfusion does not affect recurrence-free and overall survivals after curative resection for intrahepatic cholangiocarcinoma: a propensity score matching analysis. <i>BMC Cancer</i> , 2017, 17, 762.	2.6	12
53	Metavir and FIB-4 scores are associated with patient prognosis after curative hepatectomy in hepatitis B virus-related hepatocellular carcinoma: a retrospective cohort study at two centers in China. <i>Oncotarget</i> , 2017, 8, 1774-1787.	1.8	17
54	Albumin to gamma-glutamyltransferase ratio as a prognostic indicator in intrahepatic cholangiocarcinoma after curative resection. <i>Oncotarget</i> , 2017, 8, 13293-13303.	1.8	39

#	ARTICLE	IF	CITATIONS
55	Shanghai Score. Chinese Medical Journal, 2017, 130, 2650-2660.	2.3	18
56	HOXB7 promotes tumor progression via bFGF-induced activation of MAPK/ERK pathway and indicated poor prognosis in hepatocellular carcinoma. Oncotarget, 2017, 8, 47121-47135.	1.8	29
57	CCL24 contributes to HCC malignancy via RhoB- VEGFA-VEGFR2 angiogenesis pathway and indicates poor prognosis. Oncotarget, 2017, 8, 5135-5148.	1.8	35
58	Prognostic value of fever grade combined with neutrophil percentage in hepatocellular carcinoma patients presenting fever as the initial manifestation. OncoTargets and Therapy, 2016, Volume 9, 6281-6290.	2.0	5
59	Apolipoprotein A1: a novel serum biomarker for predicting the prognosis of hepatocellular carcinoma after curative resection. Oncotarget, 2016, 7, 70654-70668.	1.8	44
60	Positive <sc>HB</sc>cAb is associated with higher risk of early recurrence and poorer survival after curative resection of <sc>HBV</sc>-related <sc>HCC</sc>. Liver International, 2016, 36, 284-292.	3.9	27
61	Dual Shp2 and Pten Deficiencies Promote Non-alcoholic Steatohepatitis and Genesis of Liver Tumor-Initiating Cells. Cell Reports, 2016, 17, 2979-2993.	6.4	35
62	Overexpression of interleukin-35 associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection. British Journal of Cancer, 2016, 114, 767-776.	6.4	60
63	Caveolin-1 promotes tumor growth and metastasis via autophagy inhibition in hepatocellular carcinoma. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, 169-178.	1.5	32
64	Generation and characterization of a tetraspanin CD151/integrin $\alpha 6 \beta 1$ -binding domain competitively binding monoclonal antibody for inhibition of tumor progression in HCC. Oncotarget, 2016, 7, 6314-6322.	1.8	20
65	Mitogen-activated protein kinase kinase kinase 4 deficiency in intrahepatic cholangiocarcinoma leads to invasive growth and epithelial-mesenchymal transition. Hepatology, 2015, 62, 1804-1816.	7.3	33
66	High level of serum protein DKK1 predicts poor prognosis for patients with hepatocellular carcinoma after hepatectomy. Hepatic Oncology, 2015, 2, 231-244.	4.2	13
67	Promyelocytic leukemia protein induces arsenic trioxide resistance through regulation of aldehyde dehydrogenase 3 family member A1 in hepatocellular carcinoma. Cancer Letters, 2015, 366, 112-122.	7.2	21
68	Coexpression of gene Oct4 and Nanog initiates stem cell characteristics in hepatocellular carcinoma and promotes epithelial-mesenchymal transition through activation of Stat3/Snail signaling. Journal of Hematology and Oncology, 2015, 8, 23.	17.0	136
69	PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma. Oncotarget, 2015, 6, 846-861.	1.8	84
70	Postoperative adjuvant transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond the Milan criteria: a retrospective analysis. American Journal of Cancer Research, 2015, 5, 450-7.	1.4	18
71	Decreased Expression of GATA2 Promoted Proliferation, Migration and Invasion of HepG2 In Vitro and Correlated with Poor Prognosis of Hepatocellular Carcinoma. PLoS ONE, 2014, 9, e87505.	2.5	26
72	Neddylation pathway is up-regulated in human intrahepatic cholangiocarcinoma and serves as a potential therapeutic target. Oncotarget, 2014, 5, 7820-7832.	1.8	63

#	ARTICLE	IF	CITATIONS
73	Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2014, 20, 6212-6222.	7.0	1,012
74	Activating Mutations in PTPN3 Promote Cholangiocarcinoma Cell Proliferation and Migration and Are Associated With Tumor Recurrence in Patients. <i>Gastroenterology</i> , 2014, 146, 1397-1407.	1.3	111
75	HNRNPAB Induces Epithelialâ€Mesenchymal Transition and Promotes Metastasis of Hepatocellular Carcinoma by Transcriptionally Activating <i>SNAIL</i> . <i>Cancer Research</i> , 2014, 74, 2750-2762.	0.9	91
76	Clinical characteristics, outcome, and risk factors for early and late intrahepatic recurrence of female patients after curative resection of hepatocellular carcinoma. <i>Surgery</i> , 2014, 156, 651-660.	1.9	31
77	Down-regulation of sirtuin 3 is associated with poor prognosis in hepatocellular carcinoma after resection. <i>BMC Cancer</i> , 2014, 14, 297.	2.6	40
78	Lectinâ€based glycoproteomics to explore and analyze hepatocellular carcinomaâ€related glycoprotein markers. <i>Electrophoresis</i> , 2009, 30, 2957-2966.	2.4	69